Patient subjective assessment of drug side effects in inflammatory bowel disease

Journal of Clinical Gastroenterology

Volumn 42, Issue 3, 2008, Pages 244-251

  Cross, Raymond K ^a,c   Lapshin, Oleg ^a,b   Finkelstein, Joseph ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Veterans Affairs   (United States)

^c NONE   (United States)

Author keywords

Adverse drug reactions; Adverse effects; Inflammatory bowel disease; Side effects

Indexed keywords

AMINOSALICYLIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NARCOTIC ANALGESIC AGENT; STEROID;

ADULT; APPETITE; ARTHRALGIA; ARTICLE; BODY WEIGHT; BRUISING; CLINICAL ARTICLE; CROHN DISEASE; DAYTIME SOMNOLENCE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; ENTERITIS; FEMALE; HAIR GROWTH; HEADACHE; HEALTH CENTER; HUMAN; IRRITABILITY; JOINT SWELLING; MALE; MOOD CHANGE; OUTCOME ASSESSMENT; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; SLEEP; ULCERATIVE COLITIS; WEIGHT CHANGE;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 39749114984     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31802f19af     Document Type: Article

References (29)

1. Martin A, Leone L, Castagliuolo I, et al. What do patients want to know about their inflammatory bowel disease? Ital J Gastroenterol. 1992;24:477-480.
2. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
3. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
4. Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther. 2005;21:1211-1216.
5. Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003;98(12 suppl):S18-S23.
6. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277:301-306.
7. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29-34.
8. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
9. Dormann H, Krebs S, Muth-Selbach U, et al. Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? Aliment Pharmacol Ther. 2001;15:171-180.
10. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100:1121-1125.
11. Finkelstein J, Lapshin O, Joshi A, et al. Patient Perception of Side Effects Associated With Asthma Medications. In: Proceedings of the American Thoracic Society 2005 International Conference. San Diego, CA; 2005:A362.
12. Lapshin O, Finkelstein J. The Side Effect Survey: a New Scale for Adverse Event Assessment. R-AMA J. 2005;2:20.
13. Lapshin O, Skinner CJ, Finkelstein J. How do pyschiatric patients perceive the side effects of their medications? German J Psychiatry. 2006;9:74-93.
14. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
15. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
16. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
17. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
18. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571-1578.
19. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001;96:2921-2928.
20. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
21. Ardizzone S, Porro GB. Comparative tolerability of therapies for ulcerative colitis. Drug Safety. 2002;25:561-582.
22. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-823.
23. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Safety. 2000;23:429-448.
24. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Safety. 1991;6:192-219.
25. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058-1065.
26. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229.
27. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296.
28. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357-1361.
29. Donovan M, Lunney K, Carter-Pokras O, et al. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci. 2007. [Epub ahead of print April 7].